Uploaded March 2026 | Updated September 2026, 3 weeks ago
DISCLAIMER: No information provided here is to be construed as medical advice. Always consult with a licensed medical provider for medical advice.
Millions of people are taking GLP-1 receptor agonists like semaglutide and tirzepatide to lose weight — but what happens when they stop? A major new study published in The Lancet analyzed 18 clinical trials and over 3,700 patients to find out, and the results are something every GLP-1 user needs to know.
In this video, we break down:
Why stopping weight loss drugs triggers a rapid metabolic rebound
Exactly how much weight people regain — and how fast
How semaglutide, liraglutide, and tirzepatide compare when discontinued
What the SURMOUNT-4 trial revealed about stopping Mounjaro/Zepbound
What patients and doctors should be doing differently
Whether you're on Ozempic, Wegovy, Mounjaro, Zepbound, or Saxenda — or thinking about starting — this is essential viewing before making any decisions about stopping treatment.
📄 Study: Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis — eClinicalMedicine, The Lancet (2025): https://tr.ee/LKXQnP
Chapters:
00:00 – Intro
00:32 – What are GLP-1 Drugs?
02:04 – What the Lancet study found
03:26 – Liraglutide vs. Semaglutide vs. Tirzepatide
07:06 – Why your body bounces back
08:15 – What patients and doctors should do
09:43 – Final thoughts
Social Links
tiktok.com/@roundmoundofzepbound
instagram.com/roundmoundofzepbound
#zepbound #mounjaro #glp1 #weightloss #weightlossjourney #glp #tirzepatide #semaglutide #wegovy #ozempic #menshealth #TheWeeklyShot #HealthyMENtality #glp1news #beforeandafter #beforeandafterweightloss
DISCLAIMER: No information provided here is to be construed as medical advice. Always consult with a licensed medical provider for medical advice.
Millions of people are taking GLP-1 receptor agonists like semaglutide and tirzepatide to lose weight — but what happens when they stop? A major new study published in The Lancet analyzed 18 clinical trials and over 3,700 patients to find out, and the results are something every GLP-1 user needs to know.
In this video, we break down:
Why stopping weight loss drugs triggers a rapid metabolic rebound
Exactly how much weight people regain — and how fast
How semaglutide, liraglutide, and tirzepatide compare when discontinued
What the SURMOUNT-4 trial revealed about stopping Mounjaro/Zepbound
What patients and doctors should be doing differently
Whether you're on Ozempic, Wegovy, Mounjaro, Zepbound, or Saxenda — or thinking about starting — this is essential viewing before making any decisions about stopping treatment.
📄 Study: Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis — eClinicalMedicine, The Lancet (2025): https://tr.ee/LKXQnP
Chapters:
00:00 – Intro
00:32 – What are GLP-1 Drugs?
02:04 – What the Lancet study found
03:26 – Liraglutide vs. Semaglutide vs. Tirzepatide
07:06 – Why your body bounces back
08:15 – What patients and doctors should do
09:43 – Final thoughts
Social Links
tiktok.com/@roundmoundofzepbound
instagram.com/roundmoundofzepbound
#zepbound #mounjaro #glp1 #weightloss #weightlossjourney #glp #tirzepatide #semaglutide #wegovy #ozempic #menshealth #TheWeeklyShot #HealthyMENtality #glp1news #beforeandafter #beforeandafterweightloss
